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Due to the increase prevalence of antimicrobial resistance (AMR) antibiotic 
alternatives have been of great interest. Antimicrobial peptides (AMPs) and polymers like 
polymethacrylates that mimic AMPs are two non-traditional antimicrobial agents that 
have been investigated thoroughly over the years as a potential solution to the AMR 
problem. This study will further the understanding of the L1 peptide by investigating the 
role hydrophobic amino acids have on the antimicrobial activity. Biophysical and 
microbiological techniques were utilized to show that the L1 hydrophobic derivative 
showed enhanced binding to anionic lipid bilayers while maintaining low hemolytic 
activity. This study also elucidates the effect of charge and hydrophobicity on 
polymethacrylate polymers by imploring the same techniques and methods used to 
investigate the Ponericin L1 peptide. These results indicate that both charge and 
hydrophobicity have an impact on activity and selectivity. As hydrophobicity increased, 
so did the hemolytic activity, suggesting a balance between hydrophobicity and charge is 
needed to optimize antimicrobial activity as well as selectivity. Overall, the results show 
that these AMPs and polymethacrylates have great potential as a platform against AMR. 
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Antimicrobials and a Need for Alternatives 
 
History of Antimicrobials 
 Antibiotics are a major line of defense against infectious bacteria, a progression 
in the development of antibiotics has allowed for significant progress in medical practices 
[1]. Alexander Fleming was known for the discovery of penicillin, and the impact it had 
on the field of medicine. Although the revolutionary nature of penicillin, it was not until 
1943 that penicillin was mass produced and used commercially [2]. This was because the 
stability of the compound and the science that was available made it tougher than 
expected to purify this compound. Penicillin encompassed Paul Ehrlich’s idea of the 
“magic bullet”, which is the idea that a drug selectively targets a disease-causing microbe 
and not the host themselves. However, the unexpected problem of the purification almost 
led to the extinction to this concept until 1930 when the development of sulfa drugs 
became prevalent. A compound that was derived from oil dyes by the name of 
sulfamidochrysoidine or commonly referred to as prontosil. This was discovered to have 
limited success with its bacteriologic activity in animals but not invitro. This was 
resolved in 1935, when it was elucidated that sulfanilamide was the primary active 
compound within prontosil. This discovery not only led to a Nobel prize in 1939 but 
revived the search for the perfect “magic bullet” [3]. From 1944 to 1972 deaths caused 
from bacterial infection had decreased and a new life expectancy had jumped by eight 





Drug-target interactions are the mechanisms of a drug that occur during the 
interaction with the intended target. Four most common antibiotic target mechanisms are 
the inhibitions of DNA, RNA, cell wall, and protein syntheses. Quinolones inhibit 
chromosomal topology that is essential for the synthesis of DNA, mRNA transcription, 
and cell division. Quinolone antimicrobial agents target one of two enzymes more 
efficiently depending on the type of bacteria. Topo IV is the target in Gram-positive 
bacteria; however DNA gyrases are the target in Gram-negative [5-8]. RNA synthesis is 
another quintessential part of every cell. Antibiotics that inhibit this synthesis have a 
selectivity to target RNAP or RNA polymerase. This method of action permits a wide 
range of activity, specificity of the drug, and high efficacy. Four different classes that 
participate in this mechanism are rifamycin, sorangicin, streptolydigin, and myxopronin. 
Each class has a different binding site but have the same outcome of disrupting RNA 
synthesis [5,9,10]. Antibiotics also can affect the cell wall of a bacterial cell. Cell wall 
Biosynthesis Inhibitors (CBIs) are one of the most effective classes of antibiotics that are 
available. There are three stages of cell biogenesis that the antibiotics target to cause cell 
lysis. In the first stage or the cytoplasmic stage, an antibiotic like Fosfomycin will inhibit 
a specific enzyme to starve the bacteria cell. Tunicamycin will target the lipid II 
component of a cell, causing cell death from the second stage, the membrane associated 
stage. Beta-lactam antibiotics like penicillin are a classical example of an antimicrobial 
agent that targets proteins like the lactam binding protein to inhibit the third stage, 
extracytoplasmic stage. There are a wide range of activities for CBI’s which lead to lytic 
or non-lytic death [11]. Antibiotics also have the capability to inhibit protein synthesis 
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and is the broadest of classes of antibiotics. 30s and 50s are two subclasses and refer to 
the ribonucleoprotein that organize the initiation phase for protein synthesis. A 30S 
inhibitors like aminoglycosides will bind tightly to the 30S subunit that will cause a 
misreading in mRNA, or like tetracycline will bind to 30S and prevent addition of amino 
acids containing tRNA. Protein synthesis inhibitors of the 50S subclass have a wider 
range of activities. These inhibitors can bind to the 50S subunit and inhibits the formation 
of peptide bonds. They can also, prevent peptide elongation via binding to the peptide 
exit tunnel. Lastly, an integral part of protein synthesis is the formation of the ribosomal 
complex that initiates the process of protein synthesis. The 50S subclass can affect the 
formation of this complex preventing the process [10,12].  
Antibiotics with their wide range of activities do not affect different types of 
bacteria the same, some are more effective at killing Gram-positive than Gram-negative. 
Gram-negative bacteria have a thinner peptidoglycan layer as well as it resides between 
an outer membrane composed of lipopolysaccharides, proteins, and a plasma inner 
membrane. Gram-positive bacteria only have a doubly thick peptidoglycan and inner 
membrane. Penicillin affects Gram-positive more effectively because of its ability to 
disrupt the formation of peptidoglycan. This is because of the composition of cell wall for 
Gram-positive versus the composition of Gram-negative. The full exposure of the 
peptidoglycan layer leaves it prone to inhibition by penicillin. After this inhibition, the 
bacteria cell is fragile and more likely to burst, and because human cells do not contain a 
peptidoglycan layer it acts as a “magic bullet” and targets the bacteria specifically 
[13,14]. Staphylococcus Aureus is a Gram-positive bacterium that is selectively targeted 




A need for antibiotic alternatives has been strongly recognized since the 1960’s as 
the rise of antimicrobial resistance accelerated. Some S. Aureus strains as well as other 
bacterial strains have the capability of avoiding imminent death by mediation from a gene 
that encodes β-lactamase. Once staphylococci gain exposure to the antibiotic, a gene will 
produce the β-lactamase and this enzyme then hydrolyses the β-lactam ring of penicillin. 
S. Aureus can also develop resistance to methicillin as well. Methicillin was introduced as 
an antibiotic to combat the penicillin resistant strains of staphylococcus. This 
antimicrobial agent is a semisynthetic derivative of penicillin. It is in a class of antibiotic 
called penicillinase-resistant-penicillin. Penicillinase refers to the enzyme β-lactamase, 
and the modifications made to penicillin as an attempt at a solution to this problem. The 
strain of staphylococcus that are resistant to methicillin is referred to as MRSA or 
Methicillin Resistant Staphylococcus Aureus and the mechanism of defense against the 
antibiotic is different. This strain has a gene called mecA which produces penicillin-
binding protein 2a (PBP2). This type of protein is responsible for the cross-linking of 
peptidoglycan chains. Beta-lactam antibiotics have a poor affinity for binding to PBP2a, 
this allows MRSA to survive even at high concentrations [14,15]. 
Multidrug Resistance (MDR) much like the notorious case of S. aureus is a threat 
especially in clinical settings. MDR occurs when the active concentration of a drug is 
insufficient in killing the bacteria. This can happen by an accumulation of resistant 
plasmids or transposons that encode the resistance of specific antimicrobial agents. 
Bacteria can also use energy-dependent efflux pumps to impair the accessibility to the 
target [17,18]. In a clinical setting, nosocomial infections are a concern when considering 
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multidrug resistance. Nosocomial infections and MDR for over a century have caused a 
burden on the healthcare system, particularly in the intensive care unit (ICU). ICUs have 
extensive antimicrobial usage which may promote an emergence of MDR. This coupled 
with a patient having a compromised immune system can cause life-threatening situations 
[19]. To put this in perspective, the World Health Organization (WHO) reported an 
estimated 480 thousand new cases of a Multidrug Resistant Tuberculosis (MDR-TB) that 
occurred in 2014. Of the 480 thousand cases, 190 thousand patients died proving MDR-
TB to pose a threat to control worldwide [20]. 
Non-typhoidal Salmonella (NTS) are infections caused by all serotypes of 
Salmonella enterica with the exception of serovars Typhi and Paratyphi. 
Fluoroquinolones drugs are a common choice for treating gastrointestinal infections, for 
example NTS infections. However, several studies have shown that NTS have a 
decreased susceptibility to this treatment. According to data reported by WHO, 
fluoroquinolone resistance in NTS  are high in some countries of Africa (30%-35%), of 
Eastern Mediterranean region (46%-49%) and in Peru (96%) yet relatively low in the 
European region [125]. These problems highlight the need for the development of new 
antibiotics, ideally with low potential for resistance. 
Although MDR has a large impact and is life threatening or clinical environments, 
there are approaches to combat this problem. One of the common approaches is the use of 
a combination of antimicrobial agents. This can result in an antibiotic-antibiotic 
combination, or an antibiotic-non antibiotic adjuvant molecules to inhibit the B-lactamase 
enzyme. This approach can also use two components that will indirectly affect the 
bacterial resistance by interfering with the signaling pathway [21]. Macromolecular 
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approaches to eradicate the clinical problems of multidrug resistance are also common. 
Synthetic cationic polymers have shown to be useful, one of the most beneficial 
characteristics is the ability to reuse polymers without leading to antimicrobial resistance 
[22]. A renewed interest in western medicine is the approach of phage therapy. This 
approach uses virulent phages that act as parasites preforming lytic cycles on the bacteria. 
The mode of action for phages are highly selective, however complex difficulties led to 
slow development [23,24]. Metal-based Antimicrobials (MBAs) have also shown to be 
an effective approach against AMR. Metal ions are known to be toxic to bacteria, and 
transition metals in the D-block have been gaining increasing amount of attention for this 
approach. Metals exhibit cytotoxic effects and have seemingly endless complex 
formations, and with their electron deficiency metals readily interact with electron-rich 
biomolecules [25,26]. 
History of Antimicrobial Peptides 
 In 1939 substances under the class of gramicidin were isolated from the bacillus 
brevius. This peptide falls under a broad class of antimicrobials called antimicrobial 
peptides (AMPs). This AMP has a wide range of antimicrobial activity against Gram-
positive bacteria. Antimicrobial peptides are used in organisms as a defensive or 
offensive mechanism in nature. The difference between a small molecule antibiotic and 
an AMP is that an AMP does not rely on an enzymatic mechanism leading to cell death. 
A common well accepted mechanism of an AMP targets the envelope of the bacterium 
and not proteins or other compounds in the biosynthesis processes [27,28]. Targeting an 
integral part of cell structure is a core reason for diminished antimicrobial resistance. It 
was also elucidated in a recent investigation that the pharmacodynamics of peptides may 
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also have a part to play [29]. Antimicrobial peptides consist of a sequence of amino acids 
that can vary in length and a variation of different amino acid residues. There is a class of 
AMPs derived from the secretions of an Indian native frog called Tigerinins. This class of 
peptide is one of the smallest sequences, and the smallest represented of the antimicrobial 
peptides derived from amphibians. This class of peptide is a short sequence only 
containing 11-12 amino acids. Reported in a study done in 2001 it has shown to have 
antimicrobial activity against a broad spectrum of bacteria Gram-positive and Gram-
negative [30]. Large amino acid sequences are also effective at causing cell death. The 
range in length for AMPs can be around 12-50 amino acid residues. A recent review was 
done in 2019 comparing different antimicrobial peptides derived from multiple sources. 
This review described LL-37, an antimicrobial peptide that has 37 amino acids with two 
leucine residues at the N-terminus with traditional antimicrobial activity against Gram-
positive and Gram-negative bacteria [31]. 
Isolating antimicrobial peptides from mammals and other organisms is not an 
unusual practice in present day. AMPs have been isolated from vertebrates, invertebrates, 
plants, and even fungi. In animals AMPs are commonly found in the tissues and organs 
that are easily exposed to airborne pathogens, these AMPs act as a first line of defense.  
The progression into studies done on host defense peptides (HDPs) started in 1956 when 
the first animal host defense peptide was isolated from rabbit leukocytes. This discovery 
led to a rapid expansion into the field of antimicrobial peptides. Host defense peptides do 
as the name suggests and work directly as an antimicrobial agent, or in immune signaling, 
and in some cases work in both fashions. Defensins are an HDP were identified in the 
early 1980’s. They were described as cationic, and cysteine rich components residing in 
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mammal neutrophil phagocytes. More than 5,000 naturally occurring AMPs were 
discovered or synthesized as of 2013 [32,33] and as of 2016 there were over 23,000 
AMPs that were discovered [34]. As technology improves, more and more computer 
assisted simulations can predict valid peptide structures for antimicrobial activity [35].  
Structures and Characteristics of Antimicrobial Peptides 
 As briefly mentioned, antimicrobial peptides have a range in length typically 
between 11-50 amino acids. These sequences are amphipathic and vary in hydrophobic 
and cationic amino acids. Due to these characteristics and a positive net charge AMPs 
have shown strong activities against bacteria. However, these activities are not limited to 
just bacteria and can affect a broad spectrum of organisms.  AMPs have shown antiviral 
activity [36], antifungal activity [37], perturb protozoan homeostasis in parasites [38], 
and can even cause apoptosis in cancer cells [39]. These activities are largely impacted 
by the sequence and structure of the antimicrobial peptide. 
AMPs can be characterized by their secondary structure. These secondary 
structures can be characterized into 4 classifications including: α-helix, β-sheet, loop 
structure, and extended structures. Using peptide backbone torsion angles as an 
alternative to structural classification will show many different AMP folds [40]. AMPs 
that are classified as an α-helical structure are usually amphipathic and cationic. Helical 
peptides are the most widely distributed with a level of hydrophobicity and the broadest 
spectrum of activity [40]. β-sheet AMPs are characterized by a disulfide bond between at 
least two β-strands. These structures are more complicated, and the degrees of β-sheet 
can be extremely different between peptide sequences [31,41,42]. Antimicrobial peptide 
secondary structures are still considered poorly understood. Most will belong to the four 
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mentioned classifications however, in some cases AMPs can belong to neither of those 
classifications [40]. 
Experimental and theoretical data have shown that most AMPs are either partially 
or fully disordered in solution [43-45]. Some AMPs are unstructured in solution. 
However, AMPs have the ability to adopt an active secondary structure due to the 
hydrophobic and hydrophilic regions being in energetically favorable positions upon 
interaction with lipid membranes [46-49]. The formation of an α-helical secondary 
structure allows peptide bonds to form hydrogen bonds that will reduce the energetic cost 
of transfer. β-sheet induced secondary structures often display discrete cationic and 
hydrophobic patches [50]. AMP amphiphilicity is promoted through a steep decrease in 
polarity across the membrane and align peptide with the interface gradient. This results in 
an interface-partitioned AMP that is orientated with hydrophobic residues directed 
toward non-polar region of the bilayer and cationic residues remain close to the charged 
and zwitterionic head groups [51]. Due to the poor understanding of the active secondary 
structure, the underlying issue that if it is necessary to form this structure for disruption of 
bacterial membranes can be viewed as controversial. 
Mechanism of Action of Antimicrobial Peptides  
Since the discovery of AMPs the mode of action (MOA) has been extensively 
studied to be used as a therapeutic agent at full potential. It was previously thought that 
the only MOA of AMPs was membrane targeting. However, as understanding MOA 
progresses there is increasing evidence that there are several mechanisms [52]. The two 
major classes are direct killing or immune modulation. It was briefly mentioned that 
AMPs target the envelope however, they can also act like traditional antibiotics and target 
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DNA, RNA synthesis as well as target other specific molecules in the cell [53,54]. The 
Multi-hit mechanism upon interactions with a bacterial cell increases the efficiency of 
antimicrobial peptides [55]. 
AMPs adopt an active secondary structure upon interaction with the bacterial cell 
membrane. Amphiphilic peptides show their nature upon interaction by folding into 
amphipathic α-helices with hydrophobic and hydrophilic faces when adsorbed into lipid 
membrane. The initial interactions occur because of electrostatic interactions. The 
positively charged AMP interacts with the negatively charged cell membrane and 
undergo both adsorption and a confirmational change [56]. AMPs generally show 
selectivity with non-hemolytic activity well above their Minimum Inhibitory 
Concentration. Magainin 2 a peptide that is derived from the skin of an African claw frog 
Xenopus laevis inhibits growth of bacteria at 2-50uM. However, the concentration that 
causes hemolysis in human erythrocytes is as high as 1000uM [57,58]. The main factor in 
an AMPs ability to selectively target a bacterial cell opposed to a host cell can be 
attributed to the cationic property and the composition of membrane for bacteria. Bacteria 
cell membranes are rich in phosphatidylglycerol and cardiolipins. The cell walls also 
contain anionic lipopolysaccharides making them susceptible to being targeted by AMPs. 
Mammalian cells lack this anionic surface charge however, this isn’t the only reason for 
the prevention of AMP interaction. Mammalian cells contain a molecule called 
cholesterol that has membrane stabilizing characteristics and helps protect attack against 
AMPs [59,60].                   
It is difficult to elucidate a full understanding of the mechanism of action for 
AMPs, due to the scale of observation and myriad of pathways that AMPs can take to 
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disrupt a bacterial cell membrane. The four significant models that have been described 
are barrel-stave model, toroidal pore model, carpet model and the detergent like model. In 
the barrel-stave model peptides are initially oriented parallel to the membrane and 
eventually insert themselves perpendicularly which promotes lateral peptide-peptide 
interactions. These interactions act in a similar fashion to that of protein ion channels and 
for this model an amphipathic peptide structure is crucial. This allows for the 
hydrophobic region of the peptide to interact with the membrane and the hydrophilic 
regions to form the lumens of the channel. Similarly, the toroidal pore model will insert 
itself perpendicularly. The difference between the models is that the arrangement of 
hydrophobic and hydrophilic lipid portions is maintained and in a toroidal pore model 
they are disrupted. In this model there are alternate surfaces for the head or tail groups to 
interact with and adds ion selectivity and a discrete size. Pore formation is not the only 
model that can designate a pathway to membrane disruption. In the carpet model the 
peptides are adsorbed in a parallel manner to form a “carpet” to cover the surface, which 
then leads to unfavorable reactions. The carpet model can produce interactions to disrupt 
the membrane with a detergent like effect disintegrating the membrane by forming 
micelles. The final collapse that comes from carpet model can be explained by the 
detergent-like model or a pore forming model. However, it does not require specific 
peptide-peptide interactions, it also does not require the peptide to bury itself into the 






Physiochemical Properties of Antimicrobial Peptides 
  It is relatively easy to preform modifications to AMP sequences to help modify 
activity and target spectrum, as well as aid in stabilization and bioavailability [65,66]. 
The modifications that can be done physiologically to affect antimicrobial activity and 
target specificity are size, net charge, hydrophobicity, amphipathicity, and solubility [67]. 
Length is an important property and can be crucial to biological activity. Due to an 
entropic balance, short peptide sequences are less likely to form regular secondary 
structures. Longer sequences can overcome this with energetically favorable facial 
properties [68]. Length can also contribute to different 3D structures; however, it also has 
the possibility of increasing cytotoxicity. An investigation published in 2006 was done to 
elucidate possible effects when increasing chain length. Simple sequence repeats, (RW)n 
(where n equals 1,2,3,4, or 5) were used to investigate a possible role of sequence length 
by comparing the antimicrobial activity as well as hemolytic activity. The conclusion was 
that for this sequence that the optimal length was at n equals 3. As the length increased so 
did antimicrobial and hemolytic behaviors. Although results were similar for n = 3,4, or 5 
the sequence where n equals 3 is the best choice for efficiency in synthesis [69]. When 
designing synthetic AMPs, it is important to consider length in a manner of a cost and 
time effective product as well. 
 The net charge is determined by the summation of ionizable groups in the peptide. 
Majority of cationic AMPs (CAMPs) have two unique features one of the being a 
positive net charge of at least +2 and the other is an amphipathic character. It is theorized 
that the net positive charge is the main cause for the initial interaction due the bacterial 
membrane being negatively charged. It has been elucidated from a study that the net 
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charge of an AMP impacts the antimicrobial activity as well as hemolytic activity. A 
study was done using an established AMP named L-V13K which is a 26 amino acid that 
adopts an α-helical structure in a hydrophobic environment and has a hydrophilic 
positively charged lysine residue at the center. The V13K analogs had a net charge that 
ranged from -5 to +10. In the study it was observed that lowering the net charge to <+4 
rendered the peptide completely inactive, while systematically increasing the charge from 
+4 to +8 increased the overall antimicrobial activity while sustaining low hemolytic 
activity. However, an increase to +9 and +10 increased antimicrobial activity as well as 
unwanted hemolytic activity [70]. 
 Hydrophobic residues that reside within a given AMP have also shown to have 
influence over antimicrobial activity and hemolytic activity. Natural AMPs exist with a 
broad range of hydrophobicity and charge, commonly natural AMP sequences contain 
40-60% hydrophobic residues with a +4 to +6 charge [71]. The cationic nature 
contributes to the initial interaction with a negatively charged bacterial cell membrane, 
where the hydrophobic components facilitate partitioning into the membrane. Studies 
have shown that the hydrophobicity of an AMP has a more complex nature to the 
interactions of the cell membrane. For example, data provided by a study done on an 
AMP called C18G, when the phenyl alanine residues are replaced by less hydrophobic 
leucine residues it drove antimicrobial activity and cytotoxicity. One possible solution 
presented from the paper was that the physical orientation of the side chains could also 
play an important role in activity as well. The side chains of the hydrophobic residues 
could part take in a phenomenon similar to that of cationic side chains that exhibit 
“snorkeling” or extending out of the non-polar core of the bilayer. Although this was an 
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interesting result of the study, It was also displayed that when the AMP dropped below a 
threshold of hydrophobicity will contribute to the reduction of membrane binding, 
membrane activity, and antimicrobial activity [72]. 
 Amphipathicity is a result of having both hydrophilic and hydrophobic properties. 
This property is important because it ensures that there will be an initial interaction and 
activity with selectivity.  A study done on cecropins, a family of AMPs that have an 
amphipathic N-terminal domain and a hydrophobic C- terminal domain. It was evident 
that a substitution of proline residues in the N-terminus significantly reduced 
antimicrobial activity, highlighting the importance of an amphipathic α-helix [73,74].  
 The solubility of an AMP is vital for an initial interaction between the AMP and 
the bacterial cell membrane. A lack of solubility can cause inappropriate aggregation 
leading to a reduction of the membrane permeabilization effects [75]. Despite this 
potential flaw there are some methods to improve solubility of peptides in aqueous 
solutions. It is not uncommon to synthesize “hybrid” or “chimeric”, which combines 
AMPs or fragments of AMPs to improve properties. Polyethylene glycol moieties 
although not extensively explored, are commonly attached to AMPs to increase 
solubility. Not only does it increase solubility but improves pharmacokinetics, and half-
lives [76,77]. 
Venom-Derived Antimicrobial Peptides 
 Natural AMPs are diverse which causes difficulties in classification. AMPs can 
be classified on activity, structural characteristics, amino acid- rich species, and on source 
of the peptide [45]. Venom derived peptides have been a focus of studies and 
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modifications and can be a valid example of an AMP being classified by source. Venoms 
are complexed mixtures comprised of various enzymes and protein of different sizes that 
serve as a defense against microbes. Peptides are a major component in venoms and are 
capable but not required to be biologically active [78]. The peptides that do exhibit 
biological activity can do so in a myriad of ways. This activity includes membrane 
permeabilization, neurotoxins, and even GPCR agonist and antagonists [79]. With a 
Small size, acute specificity, significant structural stability these biologically active 
peptides are also relatively easy to synthesize making them ideal components for novel 
antimicrobial agents [80]. 
 Venoms can be classified into their mode of action and their effect. These include: 
Neurotoxins, cardiotoxins, hemotoxin, and cytotoxin. Neurotoxins can inhibit nicotinic 
acetylcholine receptors (nAChRs) and interfere with nerve transmission [115] These 
toxins can also inhibit ion movement through cellular membrane blocking the movement 
of neurons. Cardiotoxins bind to the cells of the heart and block muscle contraction 
which generally affect the heart muscle. Hemotoxins cause the destruction of red blood 
cells which primarily affect the circulatory system, blood function, and muscle tissue. 
Lastly, one of the most researched components of venoms are cytotoxins. Cytotoxins can 
affect the cell membrane, interfere with the transportation of substances, or even interfere 
with the transduction of signals across the membrane [116] 
 An increasing amount of studies have been done on membrane active peptides 
over the last 20 years. AMPs fall into one of the two classes of membrane peptides, and 
the other are cell penetrating peptides (CPP’s) [117]. A well known example of a 
membrane active AMP is a peptide derived from honey bee venom called melittin. 
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Melittin is a lytic peptide that binds to the membrane surface followed by insertion at 
threshold levels of bound peptide. This AMP can bind to membranes in milliseconds and 
adopts an amphipathic α-helical structure oriented either parallel or perpendicular to the 
plane of the membrane [118]. As the membrane active peptide melittin gained interest it 
has been shown to have anticancer activity [119], antifungal activities [120], antiviral 
[121], and not only antibacterial but in some cases specifically target drug resistive forms 
[122]. CPP’s are short sequence peptides with a positive charge and facilitate penetration 
into the cell across the membrane [123]. CPPs like transportan, a chimeric peptide 
derived from wasp venom, can act as a cargo carrier as a potential drug delivery system 
[124]. 
 Venoms like snake or spider venom are notorious for being toxic and deadly. 
However, the safety and pharmacodynamics are not the only issues with venom peptides. 
Peptides derived from venoms need to be sufficiently stable to avoid degradation, and 
these peptides go through Post Translational Modifications (PTMs) to achieve this 
stability. PTMs that are common are  amidation (C-terminal), γ-carboxylation (Glu), 
hydroxylation (Pro), sulfation (Tyr), bromination (Trp), glycosylation (Thr), 
pyroglutamation, N-C-cyclization, and isomerization from into D-amino acids [80]. 
These modifications enhance peptide properties however for possible therapeutic 
applications may not be enough or optimal. Optimizing venom peptides as therapeutics 
comes with a list of issues including formulation, cost of production, stability, selectivity, 
and MOA. 
 One of the key weaknesses of venom peptides as potential therapeutic agents is 
their low bioavailability which can be attributed to their hydrophilic nature and even their 
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small size (10-50 amino acids) [81]. This weakness results in an unfavorable mode of 
administering the peptide, which is a site of injection. A previously discussed technique 
such as the development of chimeric peptides is often utilized as a possible method to 
overcome this issue but is not the only method. Another common method is to use N-
alkylation of amino acids, typically N-Methylation is used to improve pharmacokinetics. 
Studies were done by N-methylating the cyclic peptide somatosatin. These studies 
elucidated that N-methylating at certain points of the peptide it increases the 
bioavailability by 10% [82]. Despite these issues that need to be addressed in further 
investigations, Venom-derived peptides hold valuable potential for being a model or a 
therapeutic agent.  
Background on Antimicrobial Polymers 
AMPs may be ancient weapons, evolving for millions of years and attacking 
bacterial membranes for quite some time, but they are not the only effective defense. 
Methacrylate random copolymers that can be classified as an AMP-mimetic polymers 
can inhibit the growth of Methicillen-resistant S. aureus (MRSA) and Vancomycin- 
resistant S. aureus (VRSA). Synthetic polymers can be used as an advantageous 
antibiotic that mimics an AMPs cationic amphiphilic structure while having diverse 
compositions, shapes, and architecture [83]. Due to this feature, polymers can be 
relatively easily synthesized to mimic AMPs and gain more insight into peptide SAR. 
Polymers have a myriad of advantages over peptides that include inexpensive to 
manufacture, easier to produce and alter chemically, and are more amendable in the 
integration of drug delivery systems [84]. These strengths and advantages may allow for 
the use of polymers to overcome the chemical limitations like bioavailability and oral 
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availability that prevent the use of AMPs in clinical settings. Many classes of AMP 
mimicking polymers exist already such as polynorbornenes, polycarbonates, 
polyalanines, and polymethacrylates. Also, these synthetic polymers can be chemically 
altered via facile route and obtain a broader range of chemical structures [85]. The ability 
to alter and manipulate to optimize activities is a favorable characteristic of both 
polymers and AMPs. Structure Activity Relationship (SAR) studies are relatively easy to 

















Investigation of the Role of Hydrphobic Amino Acids on The Structure-Activity 
Relationship in Ponericin L1 from Neoponera Goeldii 
 
Background to Ponericins 
Neoponera, a ponerine ant genus is comprised of 57 species of ant composed of 
very diverse morphology and behavior. This diverse genus ranges from southern Texas 
and northern Mexico to southern Brazil and northern Argentina. Within the ponerine ant 
genus, the Neoponera can be considered a cryptic species complex, this is defined as two 
or more species being classified as a single nominal species due to being superficially 
morphologically indistinguishable. This Includes sympatric species and species with a 
wide distribution [86,87]. A predatory ant in the subfamily Ponerinae, called Neoponera 
Goeldii (previously misclassified as Pachycondyla Goeldii) has been previously studied 
for the antimicrobial activities the peptides that reside in the venom exude [88]. 
The AMPs that are isolated from the venom of this ant are called Ponericins. 
There are fifteen novel peptides that have been extracted that display antibacterial and 
insecticidal activities. Of the fifteen peptides all contain cationic, amphiphilic sequences. 
Only twelve of the peptides contain a Trp residue in the N-terminal region. There are 
three classifications that a ponericin peptide can belong too: G, W, or L. Each class 
shares high sequence relationships with different known existing AMPs; Ponericins 
belonging to the G classification show similarities with cecropin-like peptides, W with 
gaegurins and melittin, and finally L sharing similarities with the natural polycationic 
peptides dermaseptins [88]. 
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The G family has seven of the fifteen novel peptides and has more than half of its 
sequence in common with cecropins. Cecropins have activity against Gram-negative and 
Gram-positive bacteria cells. These AMPs can also inhibit the uptake of proline, as well 
as cause leaky membranes. Ponericins in the W family make up another large portion of 
the fifteen novel peptides. This family has spectrum of activity against yeast, bacteria but 
also show hemolytic activity. In most sequences for both G and W families there is a 
proline residue near the middle of the sequence (11/13). In cell membranes ponericins 
naturally adopt α- helix structure [89]. 
The L family is the smallest and the most poorly understood of the ponericins. 
This family consist of two peptide sequences (L1 and L2) each with similarities to 
peptides derived from amphibians called dermaseptins. These peptides have had little 
recognition, only two papers report the activities and characteristics one of which being 
the original report by Orivel et al.. This reported only on the L2 peptide, which elucidated 
that ponericin L2 had a broad-spectrum of activity with no hemolytic activity. Ponericin 
L1 was reported in a recent study and had shown that this peptide adopts an α-helical 
confirmation, has enhanced binding to lipid vesicles with anionic lipids and little to no 
hemolytic activity. This study also had shown SARs that displayed the significance that 
net charge and group identity had on antimicrobial activity [90]. Ponericin L1 and L2 
have identical sequences except for a single amino acid at position 9, where L1 contains a 
Met and L2 has an Ile. Although the recent study elucidated information on ponericin L1, 





Name Sequence Net Charge M.W calculated M.W Found
L1 LLKELWTKMKGAGKAVLGKIKGLL 5+ 2596 2595.4
L1V VVKEVWTKMKGAGKAVVGKVKGVV 5+ 2498 2497.4
L1I IIKEIWTKMKGAGKAIIGKIKGII 5+ 2610 2608.6
L1L LLKELWTKMKGAGKALLGKLKGLL 5+ 2610 2609.2
L1A AAKEAWTKMKGAGKAAAGKAKGAA 5+ 2274 2273.5
L1F FFKEFWTKMKGAGKAFFGKFKGFF 5+ 2883 2881.2
Peptide sequences, nomenclature, and properties
Figure 1 














Note. Helical wheel diagram of L1, L1V, L1I, L1L, L1A, and L1F. Cationic residues are 
shown in blue, anionic in red, hydrophobic in green, polar uncharged in yellow, and 
aromatic are in purple. Peptide sequences and relevant properties are shown below the 






Materials and Methods 
Peptide Preparation 
 Peptide variants L1A and L1F were synthesized using standard FMOC-chemistry 
in-house. The parent peptide L1 along with L1-V, L1-I, and L1-L were purchased from 
Synthetic Proteomics (Carlsbad, California). Using a Zorbax C3 column, all peptides 
were purified via RP-HPLC eluted by a linear gradient of water to acetonitrile (both 
supplemented with 0.1% TFA). Peptide identity was confirmed using MALDI-TOF mass 
spectrometry. HPLC fractions containing the peptide were collected, pooled, lyophilized, 
and stored a at -20 C. Peptides were dissolved in H2O:ethanol 3:1 prior to use. Each 
peptide stock was made to a final concentration of 150 -200 μM then stored at 4 C. 
Lipid Preparation 
 Lipids  1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC; PC)1,2-dioleoyl-sn-
glycero-3-phospho-(10-rac-glycerol) (DOPG; PG), and 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphoethanolamine (POPE; PE) were purchased from Avanti Polar Lipids 
(Alabaster, Alabama), and stored as stocks in chloroform at −20 C. Lipids were prepared 
as 100% DOPC, 3:1 DOPC:Cholesterol (PC:Chol), 3:1 DOPC:DOPG (PC:PG), or 3:1 
POPE:DOPG (PE:PG). Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Chem-Impex 
Int'l INC.), ortho-nitrophenyl-β-galactoside (ONPG) (Research Products International 
Co.), nitrocefin (Biovision, Milpitas, California). All other chemicals and reagents were 
from Thermo Fisher Scientific (Waltham,Massachusetts), VWR (Radnor, Pennsylvania), 
or Sigma-Aldrich (St. Louis, Missouri). 
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 To form small unilamellar vesicles (SUVs) sonication or ethanol dilution methods 
were implemented [92]. In all cases, lipid vesicle preparation was the same. Depending 
on the lipid composition, appropriate volumes of lipids in chloroform were mixed in a 
glass tube and then allowed to dry under N2 gas for 15 minutes. The lipid films were then 
placed in a vacuum desiccator and allowed to dry further under a vacuum for 1 hour. For 
vesicles formed through ethanol dilution methods, 10 μL of pure ethanol was added to the 
film, and then vortex until the dissipation of the film. While continuing to vortex, the 
appropriate amount of PBS was added. For vesicles formed using the method of 
sonication, PBS was added directly to the tube while being vortexed to create 
multilamellar vesicles (MLVs). The MLV suspension was covered with parafilm and 
then placed in a high-powered bath sonicator (Avanti Lipids) and subjected to sonication 
for 20 minutes to create SUVs. 
Fluorescence Spectroscopy 
All fluorescence spectroscopy experiments were performed using a JY-Horiba 
Fluoromax4 instrument. Excitation and emission slit widths were kept consistent at 2.5 
nm. Semi-micro quartz cuvettes were utilized for each experiment. The following 
formula was used to calculate a spectral barycenter for each experiment: 
 
𝐵 =






where B is the barycenter, 𝜆 is the wavelength, and 𝑖 is the intensity at the specified 
wavelength. An entire emission spectrum from 300-400 was used the carry out the 
calculation of barycenter. 
Binding Experiments 
 Lipid binding protocols from previous experiments were used as a basis for the 
following reported data.  Peptide samples were prepared at final concentration of 2μM in 
PBS buffer (150 mM NaCl, 50 mM Na2HPO4, pH 7.0) and titrated with lipid vesicle 
stock (usually [1.0] mM total lipid). The standard for all binding assays is λex = 280 nm 
and λem = 300 to 400 nm. A sample containing only PBS and no peptide was used as a 
background to correct spectra after each addition of vesicles. 
Red-Edge Excitation Spectroscopy   
Red edge excitation shift (REES) experiments utilized excitation at 6 different 
wavelengths (λex = 280, 290, 295, 300, 305, and 307 nm) and the same emission range of 
310 to 410 nm. Samples were similarly prepared as above. A blank only containing PBS 
buffer was used as background to correct the spectra after each addition. 
TCE Quenching  
Trichloroethanol (TCE) quenching was monitored by titration of samples with 10 
μL aliquots of 10M TCE (Alfa Aesar, Haverhill, Massachusetts) into peptide samples 
prepared as described above. After each addition of TCE, Trp fluorescence intensity was 
measured using λex = 280 nm and λem = 340. Corrections to the emission intensity were 
made for background subtraction and dilutions. The slope of the linear best fit equation to 






= 1 + 𝐾𝑠𝑣[𝑄]  
where F0 is the fluorescence intensity in the absence of quencher, and F is the 
fluorescence intensity in the presence of a given concentration of quencher [Q]. 
Acrylamide Quenching 
 Acrylamide quenching was monitored by titration of samples with 10 μL aliquots 
of 4M acrylamide titrated into peptide samples prepared as described above. These 
samples contained either [0] or [0.25] mM total lipid.  After each addition of acrylamide, 
Trp fluorescence intensity was measured using λex = 295 nm and λem = 340. Corrections 
to the emission intensity were made for background subtraction, dilutions, and inner filter 
effects in the excitation path as described previously.  The same method to calculate Ksv 
was used as above. 
Circular Dichroism Spectroscopy 
 Circular Dichroism (CD) spectra were collected via Jasco J-810 
spectropolarimeter.  CD experiments with samples containing SUVs with 200 μM total 
lipid and 3 μM peptide in 0.1 x PBS buffer. Each measurement was an average of at least 
64 scans and was corrected by subtracting background spectra that did not contain 
peptide. 
Minimal Inhibitory Concentration(MIC)/Minimal Bactericidal Concentration(MBC) 
 Six different strains of bacteria were streaked on LB-Miller agar plates from a 




Genetic Stock Center, Yale University) or ATCC (American Type Culture Collection) 
(Escherichia coli D31 CGSC 5165 , Staphylococcus aureus ATCC 35556. Pseudomonas 
aeruginosa PA-01 ATCC 47085, Acinetobacter baumanni ATCC 19606). For each of the 
strains a liquid overnight culture was prepared using a single colony into fresh LB broth 
and placed in a shaking incubator for ~ 18 hours at 37 C at 225 rpm. After the incubation 
period, a 1:200 dilution was made in fresh LB broth and then used for experimentation. 
Minimal Inhibitory Concentration (MIC) determinations were performed using mid-log 
phase bacteria diluted to 5 x 105 CFU/mL. Next, 90 μL of this diluted culture was then 
pipetted into a sterile 96-well plate that contains serially diluted aliquots of the peptide 
variants to consist of a total volume of 100 μL. This plate was then incubated for 18 
hours at 37 C. Bacterial growth was determined by taking an OD600 measurement using a 
Spectramax M5 multimode plate reader post incubation. Minimal Bactericidal 
Concentration (MBC) was preformed by taking 1μL of the culture from the MIC plate 
and then pipetting it on to a fresh LB agar plate. After plating this culture, the plate was 
then incubated overnight at 37 C. MBC was determined by the growth or the lack of 
growth from each well on the agar plate. 
Bacterial Inner Membrane Permeabilization Assay 
A single colony of E.coli D31 was inoculated into LB broth and placed in a 
shaking incubator and set to 225 rpm at 37 C for ~ 18 hours. A 1:250 dilution was made 
using the overnight culture into fresh LB broth. To induce the expression the expression 
of β-galactocidase, A final concentration of 100mM of IPTG was introduced. This 
dilution plus the IPTG was placed back into the shaking incubator for about 2 hours until 
an OD600 of 0.2-0.4 was achieved. 
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 A 96 well plate was prepared with the following solutions in order: 10 μL of each 
peptide variant 2-fold serially diluted down the plate with the exception of the final row 
(used as a negative control 10 μL of 0.01% acetic acid), 56 μL Z-buffer (60mM 
Na2HPO4, 40mM NaH2PO4, 10mM KCl, 1mM MgSO4, 50mM β-mercaptoethanol pH 7), 
19 μL of the E.coli culture, and 15 μL of 4 mg/ml ONPG that was prepared in Z-buffer 
added immediately before the assay began. Absorbance measurements were taken at 420 
nm every 5 minutes for a total run time of 90 minutes. The detergent 
cetyltrimethylammonium bromide (CTAB) was used as a positive control. The data 
presented is an average of three replicates. 
Bacterial Outer Membrane Permeabilization Assay 
 A single colony of E.coli D31 was taken from an LB agar plate and inoculated 
into fresh LB broth with 100 μg/mL ampicillin (LB-Amp), then place in a shaking 
incubator at 37 C (225 rpm) for ~ 18 hours. After the incubation period 100 μL was taken 
from the culture and diluted with 25 mL of fresh LB-Amp. The dilution was further 
incubated in the same conditions until an OD600 of 0.2 to 0.4 was obtained. Once the 
specified OD600 was reached the culture was then centrifuged at 2500 rpm for 15 minutes 
in a tabletop clinical centrifuge. The supernatant was discarded and then an equal amount 
of PBS (100 mM NaH2PO4, 200 mM NaCl, pH7) was used to resuspend the pellet. 
 Experimental samples were prepared in a 96-well plate in the order as follows: 10 
μL of the six peptide variants that were serially diluted starting a concentration of 15 μM 
with the exception of the last row (used as a negative control 10 μL of 0.01% acetic acid). 
80 μL of the resuspended bacteria culture, and 10 μL of 50 μg/mL nitrocefin in PBS. The 
absorbance was recorded at 486 nm in 5-minute intervals for a total run time of 90 
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minutes immediately following the addition of nitrocefin. The antimicrobial agent 
polymyxin B was used as a positive control. The values presented are the average of three 
replicates. 
Hemolysis 
Hemolysis on Sheep red blood cells (RBCs) was used to quantify the 
destabilization of membranes by leakage of hemoglobin. Sheep blood was obtained 
through Hemostat Laboratories and stored at 2 – 8 C. A 7 mL aliquot of whole sheep 
blood was mixed with 7 mL of sterile PBS at pH 7.4. The solution was sedimented via 
centrifugation for 7 minutes at 2500 rpm. Supernatant was removed and the pellet was 
resuspended to the original volume of 14 mL. This was repeated three times and the final 
pellet was resuspended to 14 with PBS. Next, 90 μl of the cell suspension was pipetted 
into all wells of a conical bottom 96-well plate. 10 μL of serially diluted peptide variant 
or the detergent TX-100 (positive control) were added to the wells prior to addition of the 
RBC’s. The plate was covered and left in a shaking incubator at 37 C at 150 rpm for 1 
hour. Post incubation the plate was then centrifuged for 10 minutes at 200 rpm at 4 C. 6 
μL of the supernatant was added to 94 μl of fresh PBS in a flat bottom plate. The 
absorbance of the plate was taken at 415 nm using a Spectramax M5 multimode plate 
reader. By using the absorbance of each well compared to the wells without additive and 
those with Triton-X 100 a percentage of hemolysis was calculated. The data presented are 







 All peptides in this study were synthesized via solid-phase peptide synthesis 
approaches and purified by reversed-phase HPLC.  The sequences used in this study and 
relevant physio-chemical properties are shown in Figure 1A.  As the L1 peptide has 
previously been shown to adopt an α-helical conformation when bound to lipid bilayers, a 
helical wheel diagram of the parent L1 sequence is shown in Figure 1B. 
Antimicrobial Activity 
 The ability of L1 and the hydrophobic variants to act as antimicrobials was 
investigated using the Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal 
Concentration assays as previously described [96].  The MIC is determined as the lowest 
concentration of peptide required to inhibit bacterial growth in solution, while the MBC 
is the lowest concentration required to act in a bactericidal mechanism (as opposed to 
bacteriostatic) and is determined by plating MIC cultures on antimicrobial-free media.  
Peptides were screened against E. coli, S. aureus, A. baumanii, P. aeruginosa, B. subtilis, 








MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC
L1 7.50 15 0.94 0.94 1.875 3.75 >15 >15 0.469 0.938 3.75 >15
L1V >15 >15 >15 >15 >15 >15 >15 >15 >15 >15 >15 >15
L1I 15 15 0.469 3.75 1.875 1.875 >15 >15 0.469 0.469 7.5 7.5
L1L 1.875 3.75 0.469 0.938 0.938 0.938 15 >15 0.469 0.938 3.75 >15
L1A >15 >15 >15 >15 >15 >15 >15 >15 >15 >15 >15 >15
L1F 0.938 1.875 0.938 >15 0.469 0.938 7.5 >15 1.875 1.875 1.875 7.5
B. subtilis K. pneuomiaeS. aureus E. coli A. baumanii P. aeruginosa
Table 1 









Solution Aggregation Properties 
 Considering that the first step in the mechanism of action of many AMPs is the 
binding to the bacterial cell surface, any aggregation or oligomerization of peptides can 
impact the binding equilibrium.  If amino acid substitutions promote the aggregated state, 
this will then reduce the amount of free peptide available to bind the bacteria and exert 
antimicrobial activity.  This is especially relevant in reference to hydrophobic 
substitutions as hydrophobicity of a peptide is a significant driver of peptide aggregation 
in solution [93-95]. 
      Aggregation of peptides was assessed utilizing the intrinsic fluorescence properties of 
the Trp residue in the L1 sequence.  Since L1 contains a single Trp, this residue can serve 
as a reporter for a variety of peptide characteristics, most notably the environment that 
the Trp, and thus the peptide, is sampling.  Differences in the side chain motion/dynamics 
of the Trp residue and the local environment around the Trp can be observed by 
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monitoring the red-edge excitation shifts (REES).  This approach monitors shifts in the 
emission spectrum as a function of varying the excitation wavelength which is directly 
influenced by the mobility and solvent accessibility of the Trp side chain [96].  When a 
Trp is exposed to the aqueous milieu and is free to sample rotational conformations, no 
REES is exhibited, while if the Trp is constrained or shielded from bulk water REES is 
observed as the excitation wavelength is increased.  The REES results are shown in 
Figure 2A.  Notably, all peptides exhibited some degree of REES, with L1V exhibiting 
the strongest REES of ~10 nm. Conversely, the L1F peptide exhibited the least REES, 
only ~2 nm.   
The environment of the L1 Trp residue was further probed using fluorescence 
quenching by trichloroethanol (TCE) which selectively exerts quenching on Trp residues 
which are shielded from the aqueous milieu, such as at the interior of a peptide aggregate.  
The results are shown in Figure 2B, with the Ksv values for the quenching shown in table 
2.  The majority of the peptides showed similar extent of quenching by TCE except the 
L1A variant.  The Trp quenching in this peptide sample was markedly lower than the 
others.  However, considering the reduced overall hydrophobicity of this peptide and thus 
higher aqueous solubility, decreased TCE quenching is not surprising.  Importantly, the 

























Note. (A) Red Edge Excitation shift (REES) and (B) Trichloroethanol (TCE) quenching. 
The inset column in panel A represents the total shift (nm) for each peptide. In both 
panels L1V is shown in Light blue, L1I orange, L1L grey, L1A yellow, and L1F black. 
Peptide concentration was 2µM in all samples. All data are averages of three replicates 












L1V 9.47 ± 1.3
L1I 7.59 ± 4.9
L1L 7.39 ± 3.5
L1A 4.01 ± 0.91
L1F 8.08 ± 5
Ksv[M-1]
Table 2 








 Considering that the first step in the mechanism of action of many AMPs is the 
binding to the bacterial cell surface, binding to model lipid vesicles was performed.  
These experiments exploited the inherent environmental sensitivity of Trp as a reporter 
for binding to bilayers.  In aqueous solution, the Trp fluorescence exhibits a red shifted 
emission barycenter, while when bound to bilayers and thus in a more non-polar 
environment the Trp emission blue-shifts to lower wavelengths [97,98].  The impact of 
lipid composition on binding to model vesicles was investigated using a simple vesicle 
titration experiment in which Trp fluorescence was measured after addition of lipid 
vesicles.  The change in the emission barycenter compared to that in absence of vesicles 
was plotted as a function of total lipid concentration (Figure 3).  Lipid composition of 
vesicles was either 100% DOPC, 3:1 DOPC:DOPG, 3:1 POPE:DOPG, or 7:3 
DOPC:Cholesterol.  The results show varied behavior that is both peptide and lipid 
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composition dependent.  The L1L and L1I variants show significantly larger shifts in Trp 
emission barycenter when binding PG-containing bilayers, indicating that electrostatic 
forces are a strong driver in the bilayer association of these peptides.  In contrast, L1F, 
L1V, and L1A showed no significant preference for anionic vs. zwitterionic bilayers.  
However, only the L1F showed significant shifts in barycenter with the addition of lipid 
while L1A and L1V did not.  The L1F results indicate that binding in this case is driven 
more strongly by hydrophobic interactions independent of the electrostatic contribution.  
The L1A and L1V results indicate little interaction with the bilayer, or perhaps only very 
shallow interactions with the surface of the bilayer which does not result in a significant 








































Note. Peptide binding was assayed using TRP fluorescence by titrating SUVs into a 
peptide containing sample with a final concentration of 2 μM. After each addition the 
spectral barycenter was calculated and then a Δ barycenter was calculated by taking the 
difference between the initial barycenter and that of each addition. Peptide variants that 
were assayed were (A) L1V, (B) L1I, (C) L1L, (D) L1A, (E) L1F. In all panels Blue 
represents PC, Orange 3:1 PC:PG, Grey 3:1 PE:PG, and Yellow 3:1 PC:Chol. All data 






















Note. Normalized Trp emission spectra for L1V (A), L1I (B), L1L (C), L1A (D), and L1F 
(E) peptides before (red) and after (blue) interacting with lipid vesicles. Data are 
representative spectra after subtraction of a background spectrum. All shifts 








In order to gain more insight into the bilayer interactions, fluorescence quenching 
approaches were utilized.  The peptides were exposed to the aqueous quencher 
acrylamide in solution or when bound to vesicles.  Acrylamide is known to strongly 
quench Trp fluorescence in aqueous environments but does not exert the quenching effect 
if the Trp is buried in the non-polar core of the bilayer [99].  Thus, peptide Trp exposure 
to the aqueous milieu can be gauged by the extent of quenching by acrylamide.  Stern-
volmer quenching plots were created to analyze the data and Ksv (slopes of a linear fit to 
the data) are shown in Table 2.  The trends in this data are consistent with the barycenter 
shift data in Figure 3.  In the case of L1L and L1I, there was a significant reduction in 
quenching between the solution (free) state of the peptide and when bound to anionic 
vesicles, but a much smaller reduction if any when interacting with zwitterionic vesicles.  
This is consistent with a more deeply buried Trp in anionic bilayers.  The L1V and L1A 
exhibited differential behavior in this experiment with L1V showing a reduction in 
quenching with vesicles, indicating some interaction while the L1A did not exhibit 
significant reductions indicating that the Trp is significantly exposed under all conditions.  
Importantly, the L1F was the only peptide to exhibit extensive reductions in quenching 



















Note. Abbreviations: DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPG, 1,2- 







































Note. Acrylamide quenching was done on (A) L1V, (B) L1I, (C) L1L, (D) L1A, (E) L1F. 
Samples contained either no lipid vesicles (Dark Blue) or (Orange ) PC, (Grey) PC:PG, 
(Yellow) PE:PG, and (Light Blue) PC:Chol. All samples contained a peptide 
concentration of 2 µM and lipid concentration of 250 µM for those that contained lipid 
vesicles. Data is corrected for inner filter effects and are background subtracted. Data 




Peptide Secondary Structure 
While many venom peptides that act as AMPs adopt helical secondary structures, 
it is also known that amino acids have differing propensities to form alpha-helical 
structures.  Circular dichroism (CD) spectroscopy was used to characterize the secondary 
structure of the peptides in the absence and presence of lipid vesicles.  The CD spectra 
were recorded of the peptides in buffer or in the presence of DOPC vesicles.  DOPC was 
selected as 4/5 peptides appear to interact with these bilayers and the favorable 
spectroscopic profile of DOPC vesicles compared to those containing PG.  The CD 
results are shown in Figure 5.  In buffer alone, all peptides exhibited canonical spectral 
signatures consistent with disordered secondary structure except L1V.  When in the 
presence of lipid vesicles, L1F, L1L, and L1A clearly adopt α-helical conformations 
while L1I appears to have some helical character but not nearly as much as the other 3 
peptides.  Interestingly, there was almost no difference in CD spectra for the L1V peptide 
in the presence or absence of vesicles.  The L1V peptide exhibited a strong negative band 


































Note. Spectra of all peptide variants represented by panels (A) L1V , (B) L1I, (C) L1L, 
(D) L1A, (E) L1F, each with a final concentration of 3μM. Spectra of all peptides were 
collected in 10X diluted PBS represented with blue, DOPC represented by orange, and 
3:1 PE:PG represented by grey. All spectra collected with lipids were done in the 
presence of 200 μM lipid vesicles. All data represent the average of 64 scans with 






  The mechanism of action of the L1 venom peptide is likely a membrane 
disruptive mechanism, the effect of the hydrophobic substitutions on membrane 
permeabilization was investigated using E. coli and ovine red blood cells (RBCs).  The 
permeabilization of the E. coli outer membrane was assayed using an enzyme-substrate 
pair in which the enzyme (β-lactamase) is located in the periplasmic space while the 
substrate (the chromogenic nitrocefin) is added to the exterior of cells.  Normally, 
nitrocefin has limited permeability across the bilayer, but as peptides or other membrane 
active agents disrupt bilayer integrity, the nitrocefin can more easily cross the outer 
membrane into the periplasm where it is hydrolyzed by β-lactamase into a colored 
product.  A snapshot of the results after 30 minutes of exposure are shown in Figure 6A, 
with full time courses shown in Figure 7.  In this assay, L1L and L1F showed increased 
permeability of the outer membrane, but L1F induced permeabilization more quickly and 
at lower concentrations that L1L.  Notably, several other peptides induced some extent of 
delayed permeabilization at the highest concentrations tested, however L1I, despite the 
similar biophysical behavior demonstrated earlier, exhibited no membrane disruption 
above background.  Similarly, the permeabilization of the E. coli inner membrane was 
assessed using a cytoplasmic enzyme, β-galactosidase, and a chromogenic substrate, 
ONPG.  A snapshot of the results after 30 minutes of exposure are shown in Figure 6B, 
with full time courses shown in Supplemental 8.  In this case, only L1L and L1F 























Note. E. coli, (A) outer membrane and (B) inner membrane permeabilization. For both 
panels L1 is shown in pink, L1V in blue, L1I in orange, L1L in grey, L1A in yellow, L1F 
in black, and positive control in dark blue. All data are averages of three replicates and 































Note. The data sets show absorbance at 486 which indicates the periplasmic enzyme β-
lactamase breaking down the substrate nitrocefin. Bacteria were exposed to (A) L1, (B) 
L1V, (C) L1I, (D) L1L, (E) L1A, (F) L1F, (G) Polymyxin. The legend shows the colors 
that represent each concentration that starts from 15 µM and diluted down to 0.234 µM 

























Note. These data sets show the breakdown of the ONPG substrate by the periplasmic 
enzyme β-galactocidase which is represented by the absorbance at 420 nm. Varying 
concentrations of (A) L1, (B) L1V, (C) L1I, (D) L1L, (E) L1A, (F) L1F, (G) CTAB. The 
legend shows the colors that represent each concentration that starts from 15 µM and 
diluted down to 0.234 µM and 0 µM being the negative control. Data represents the 






Hemolytic activity of venom peptides and, more broadly AMPS in general, has 
often been a first approximation toward assessing potential for further development.  
Highly hemolytic peptides are unlikely to become useful clinical therapeutics due to the 
toxicity to the host.  Venom peptides, often suffer from high hemolytic activity due to the 
evolutionary nature of these molecules and the original purpose in the source organism. 
Additionally, it has been demonstrated that the overall hydrophobicity of antimicrobial 
polymers directly impacts the cytotoxic and hemolytic activity of these molecules, thus 
screening these hydrophobic-substituted peptides for hemolysis is an important step. The 
peptides were co-incubated with freshly isolated ovine red blood cells and peptide-
induced hemolysis was determined by comparing hemoglobin leakage from treated cells 
with the detergent Triton X-100 to that of untreated cells as a positive control.  The 
results of hemolysis assays are shown in Figure 10.  The results indicate that none of the 
L1 variants induced any measurable hemolysis up to 15 µM peptide.  These results are 
consistent with the previous results from on the L1 parent sequence and other sequence 

























Note. Hemolysis of RBCs. Data sets in 10, were normalized with the experimental data 
done on untreated RBCs (0% hemolysis) and RBCs treated with Triton X-100 (100% 
hemolysis). For this panels L1 is shown in Pink, L1V in Blue, L1I in Orange, L1L in 
Grey, L1A in Yellow, and L1F in Black. All data are averages of three replicates and SD 














Effects of Hydrophobic Residues 
  The work presented herein describes an investigation into hydrophobic amino 
acids and how a uniform substitution strategy impacts the biophysical and 
microbiological activity of the venom derived peptide Ponericin L1. Overall, the behavior 
of the peptide can be dramatically impacted by the substitution of hydrophobic residues 
in different ways, depending on the identity of the substitutions. 
While many AMPs have evolved to selectively target bacterial cell membranes 
over host cell membranes, the same selective pressure is not present for venom peptides.  
Notably, venom peptides generally act as an offensive weapon against predators or prey 
and would generally benefit from being more broad-spectrum in activity in this role 
[89,101,102].  However, any hope of development of a membrane-active peptide into a 
clinical therapeutic must have the ability to discriminate between host cell membranes 
and bacterial cell surfaces.  The biophysical results clearly show differences in affinity to 
model lipid vesicles.  The L1L, L1I, and L1F all show a significant change in emission 
barycenter upon exposure to anionic lipid vesicles.  This indicates that the peptides are 
interacting with the vesicles and the Trp residue undergoes a change in local environment 
into a more non-polar environment.  This is consistent with the physical properties of the 
peptides as these three molecules have a net positive charge and are the three most 
hydrophobic peptides when evaluated using the Wimley-White hydrophobicity scale 
[103].  However, the L1F is the only peptide to bind zwitterionic lipid vesicles over 
similar concentration ranges and resulting in similar extent of spectral shift (~14 nm). 
L1F was also the only peptide variant that showed enhanced binding to lipid composition 
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PC:Chol. However, it has been seen in other published work that the aromatic structure in 
phenyl alanine has a specific affinity for binding to cholesterol which is a likely cause for 
the binding displayed [161].  This is also likely driven by the increased hydrophobicity of 
the molecule compared to L1L and L1I.  On the other hand, the L1A and L1V peptides 
did not show nearly as much binding to the vesicles.  While these are less hydrophobic in 
general, the L1V exhibited the least shift despite being more hydrophobic than L1A. 
The interaction with anionic model lipid bilayers appears to follow the same 
pattern as the MIC results.  The weakest binding L1A and L1V peptides showed no 
antimicrobial activity at the highest concentrations tested (15µM).  Conversely, L1L, L1I, 
and L1F exhibited broad spectrum activity against both Gram-positive and Gram-
negative strains.  Similarly, these three peptides exhibited the least quenching by 
acrylamide.  Taken together, the binding to bilayer surfaces and the ability to interact 
with the nonpolar core of the bilayer appears to be a good screening tool for these 
peptides.  Beyond this, the hydrophobic component in binding appears to have a 
threshold effect on both the blue-shift of the Trp fluorescence and the antimicrobial 
activity.  Spectroscopically, the more hydrophobic peptides likely partition deeper into 
the bilayer, burying the Trp in a more non-polar environment shield from acrylamide.  
Similarly, this partitioning depth has been shown by our group and others to be a 
contributor to antimicrobial activity [72,104-106].  However, the correlation of binding to 
antimicrobial activity is not universal. Prior work from our group on a different peptide, 
C18G-His, demonstrated that peptide exhibited a strong blue shift upon binding at neutral 
pH but did not have strong antimicrobial activity at that pH regime [107].  Thus, while 
this correlation between binding and activity is suggestive for L1, care must be taken to 
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ensure that multiple avenues are examined when using experiments to guide design of 
novel peptide antimicrobials. 
An interesting result from this work is the complete lack of activity exhibited by 
L1V.  This was somewhat surprising due to the hydrophobic nature of the peptide 
coupled with the strong cationic net charge.  An examination of the data indicates that 
this is likely driven by structure formation in the peptide while in solution.  The L1V 
peptide exhibited the highest quenching by TCE in solution as well as exhibiting the 
highest degree of red-edge shift, indicative of solution interactions in the peptide.  The 
CD spectra show no difference in the absence or presence of lipid vesicles, supporting the 
binding results that L1V does not interact with bilayers.  Additionally, the CD spectra for 
L1V exhibit a minimum ~205nm, somewhat red-shifted for a disordered structure and 
blue-shifted for a b-strand.  However, similar spectra have been reported for β-turn AMPs 
by several different groups [108,109].   This formation of some β-strand structure is 
consistent with valine having a lower helical propensity than the other residues examined 
[110,111].  The structure prediction algorithm, iTasser, was used to generate predicted 
structures of L1L and L1V which also support the formation of β-strand formation in 
L1V. Although this was accurate for L1V, this did not support all structures that was 
shown by the circular dichroism. This could be due the fact iTasser uses a “B-factor” 
which indicates the inherent thermal mobility of the Trp residue. This is deduced by 
using a threading template of proteins in combination of sequence profiles [112]. This 
would not account for solvent differences and will vary in secondary structure, thus the  
α-helical confirmations predicted were incorrect for the peptides in solution. Taken 
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together, the data support the hypothesis that the activity of the peptides is a balance 















Note. Models presented are predictions generated through the algorithm, iTasser. The 
panels (A) L1, (B) L1V, (C)L1I, (D) L1L, (E) L1A, (F) L1F represent the most likely 





Finally, the lack of hemolytic activity of these peptides is striking.  While not 
totally unexpected based on prior results with L1-based sequences with substitutions to 
the cationic residues, it is exciting that these molecules retain this beneficial property 
even upon hydrophobic substitutions.  Prior studies with AMP-mimetic polymers show a 
clear relationship between overall hydrophobicity and cytotoxicity and/or hemolytic 
activity [113,114].  In those works, the Kuroda group performed hemolysis assays on a 
series of heteropolymers in which the fraction and type of hydrophobic monomers were 
varied.  These results clearly showed as the fraction of hydrophobic monomers increased, 
or the hydrophobicity of the monomers increased (methyl vs. butyl), the hemolytic 
activity also increased [113,114]. However, it appears in the L1 background that even the 
most hydrophobic substitutions (L1L and L1F) do not cross the threshold for inducing 
hemolytic activity.  Speculatively, the strong interactions between L1F and zwitterionic 
bilayers may indicate that the hemolytic threshold is not far off, as it indicates the peptide 





















As dicussed AMPs have promising potential as potential therapuetic agents.  As 
briefly mentioned in chapter 1, macromolecular approaches have also shown potential for 
therapeutic agents. Polymers potential as antimicrobial agents have been discovered since 
1965 and have been gaining attraction in both academic and industrial research [126]. By 
2013 there were 27,845 patent issued for antimicrobial polymers. Many promising 
antimicrobial polymers have been reported, and the amount of FDA-approved 
antmicrobial polymers have drastically increased in the past decades [127]. Antimicrobial 
polymers can have two different types of action that include either passive or active 
action. Passive polymer  layers that reduce protein adsorption, preventing bacterial 
adhesion on their surface. Active polymers actively kill bacteria that adhere to their 
surface. Interestingly enough both types of polymers rely on electrostatic interactions. 
However, passive polymers have reppelling characterisitcs and do actively interact or kill 
the bacteria. Active polymers can act much like AMPs and interact with cellmembranes 
in disruption[126]. 
Polymethacrylates 
Synthetic polymers have cationic, amphiphilic structures designed for membrane 
disruption. However, the major draw back to synthetic polymers is that they are often 
toxic to human cells or there is a lack of understanding of their toxic profiles. One of the 
ways to combat this issue is to design sytnehtic polymers mimicking functional and 
structural properties of less toxic host defense peptides like AMPs. Over the last decade 
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new antimicrobial polymers have been developed including copolymers of β-lactams 
[128], polynorbornenes [129], polymethacrylates [130,131], and polystyrenes [132,133]. 
Polymethacrylates are a class of materials that have a wide range of properties and many 
commercial applications including: high-preformance engineering plastics, energy 
storage materials, functional coatings, and biomaterials. One favorable trait of 
polymethacrylates is the adjustability. The diverse range of ester groups that can be 










Note. Figure 12A and 12B were modified from a scientific article from the Encyclopedia 
of Polymeric Nanomaterials [151]. (A) is methyl methacrylate (MMA) and (B) is the 










Synthetic polymers have been widely used as biocides or used in combination 
with other antimicrobials [152-154]. These syntheitc biocides are cationic, amphiphilic 
structure that are designed to cause membrane disruption. The draw back to most of these 
polymers is the inherent cytoxicity of polymers to human cells. To combat these issues 
the design of these polymers were oriented around the much less toxic host-defense 
peptides. These peptidomimetic polymers over the last decade have been further finely 
tuned to increase favorable traits such as functionality, amphiphilic balances, polymer 
sizes, antimicrobial activity, and decrease hemolytic activity [152,155-158]. 
Polymethacrylates can be finely tuned for antimicrobial activity and selectivity through 
the modifcation of the composition of cationic and hydrophobic groups much like AMPs. 
This is evident by a recent study on the role of hydrophobicity and hemolytic activty of 
polymeacrylate derivatives. In the study it was elucidated for these polymethacrylate 
derivatives that as hydrophobicity increased, so did antimicrobial activity and hemolytic. 
Although there was a lack of selectivity that could be caused by the inherent property of 
those synthetic polymers, this study gives insight that composition can dictate overall 
activity [150]. 
Indole Polymers 
In biological and biochemical structures indoles are ubiquitous with attracted 
interest in multiple areas such as pharmaceuticals, fragances, agrochemicals, and dyes. 
This can be attributed to tbeir unique elctrical, chemical, and optical properties [135-
136]. The multiple reaction sites on the indole group allow for easy tunability [137,138]. 
Side chain tryptohphan-substituted polymers have gained traction for their inherent 
fluorescence, making it easy for tacking in biological systems and molecular imaging 
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[139]. Fluorescence of proteins through the excitation of L-tryptohphan residues is well 
known and a commonly practice diagnostic tool to explore their conformation [140]. It 
also has been demonstrated that L-tryptophan-rich peptides play a significant role in 
membrane penetration [141,142]. 
Due to structure and characteristics of indole polymers, they may mimic other 
traditonal Trp-rich peptides. For example indole polymers may serves as good mimetics 
of AMPs like indolicidin and tritrpticin. Indolicidin, a 13 residue peptide in which 5 of 
them are Trp residues, is one of the shortest naturally occuring and linear AMPs. This 
AMP is a fairly attractive lead molecule for it’s potency, selectivity, and wide range of 
activity [147]. Tritrpticin is a member of the cathelicidin family and is another Trp-rich 
(3 Trp residues), short sequenced  AMP. However, tritrpticin has an extra positive charge 
compared to indolicidin with four positively charged residues localized at the C- and N- 
terminus [148]. Interestingly enough these AMPs do have  a traditonal mode of action. 
Trp-rich AMPs (TrAMPs) like these cross the bacterial membrane and interact with 
intercellular targets. Although these peptides have a broad range of activity, they do not 
affect the integrity of the membrane.[149] For example both these peptides cross the 
bacterial membrane and interact with DNA to inhibit protein synthesis, causing cell death 
[147,148]. 
Of the many types of antimcrobial polymers that have been developed, cationic 
polymers have gained the most attention. They mainly consist of cationic and 
hydrophobic functional groups with mechanisms mimicking AMPs [143]. The cationic 
functional groups, much like AMPs, facilitate the adsorption on to the surface of the 
cellular membrane. This coupled with hydrophic properties of the L-tryptophan side 
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chains could lead to increased antmicrobial activity. For example, there was a study done 
on synthisized cationic star-shaped polypeptides with 3 to 8 arms evaluating their 
antimicrobial activities. The study showed that increasing the amount of arms of the 
polypeptide resulted in an increase of antimicrobial activity, anything passed 8 arms had 
no significant increase. More imporantly for each number of arms, when the L-lysine was 
modified to be an indole group, it resulted in the best antimicrobial activity. It also 
exhibited improved cytotoxicity without comprimising the hemolytic activities [144]. 
This shows a potential in controlling the compositon of indole and cationic groups to 









































Note. Both figures 9A and 9B are modified figures from a publication from ACS Macro 
Letters [145]. Both series of polymethacrylates were synthesized and synthesized by our 
collaborators at Commonwealth Scientific and Industrial Research Organization (CSIRO) 
in Melbourne Australia. Random copolymers containing Amine-Indole side chains (PAI-
1,PAI-2,PAI-3 (red)) as Lysine-Tryptophan mimics and Gaunidine-Indole side chains 



















Materials and Methods  
Preparation of Polymethacrylates 
Random copolymer series PAI and PGI were synthesized and obtained by our 
collaborators in Australia Common Wealth Scientific and Industrial Research 
Organization (CSIRO). The average molecular weight for each series was calculated 
using H NMR end group analysis. PAI-1, PAI-2, PAI-3 had average molecular weights of 
5600, 6300, 5300 g/ mol respectively. PGI-1, PGI-2, and PGI-3 had average molecular 
weights of 6000, 6500, and 5700 g/ mol respectively [145]. PAI (Amine-indole side 
chain) was synthesized to mimic as Lysine-Tryptophan mimics. Each polymer has a 
different mass percentage of the indole side chain, PAI-1 (31%), PAI-2 (19%), and PAI-3 
(5%). PGI (Guanidine-indole side chains) was synthesized to mimic Arginine-
Tryptophan Mimics. Each polymer has a different mass percentage of indole side chain 
PGI-1 (33%), PGI-2 (19%), PGI-3 (6%). 4 mgs of polymer was weighed out and 
dissolved in .5 mL of dH2O to make an 8 mg / mL stock for experiments.  
Lipid Preparation 
 Lipids were obtained prepared in the same manner and concentrations as 
previous chapter. 
Binding Experiments 
 Binding experiments were prepared and preformed in the same manner as 
previous chapter. However, a PC:Chol composition was not tested and the final polymer 






  Acrylamide quenching experiments were prepared and preformed in the same 
manner as chapter 2 without a PC:Chol composition and with a final polymer 
concentration of .1mg / mL in the same PBS buffer as chapter 2. 
10-DN Quenching 
10-Doxyl nonadecane (10-DN) was purchased from Avanti Polar Lipids 
(Albaster, Alabama). 10-DN stock was made by taking a single ampule and diluting it 
with 1 mL of 200 proof ethanol for a final concentration of 2.7 mM. Lipid vesicles in the 
same manner as acrylamide quenching with the exception of of drying down 10-DN with 
lipid compositions. To do this, 10% of the final lipid concentration used in the acrylamide 
protocol would be replaced with 10-DN. The following changes to lipid compositions are 
as follows: 100% DOPC will be change to 90:10 (DOPC:10-DN) , for PC:PG the new 
ratio will be 65:25:10 (PC:PG:10-DN), and for PE:PG the new ratio will be 6:25:10 
(PE:PG:10-DN). Flourescence readings were taken at excitation: 280 nm and emisson: 
340 nm. 
Inner and Outer Membrane Permeabilization 
Both experiments were prepared and preformed in the same manner as the 
previous chapter, with the excpetion that the final concentration of Polymer started at .1 
mg / mL and then serialdiluted down to .0016 mg / mL , with a negative control in the 







Hemolysis was prepared and preformed in the same manner as the previous 
chapter, with the excpetion that the final concentration of Polymer started at .1 mg / mL 
and then serialdiluted down to .0016 mg / mL , with a negative control in the last well. 
Results 
Lipid interactions 
The mechanism to cationic biocides are likely to mimic that of traditional 
membrane disrupting AMPs. To do this the first step would be to bind to the surface of 
the bacterial cell. Similarly, to chapter 2, the inherent environmental sensitivity of the 
indole side chain was utilized to elucidate the membrane binding capabilities of each 
polymethacrylate series. Much like the Trp residue in the previously discussed AMPs, the 
indole side chain will exhibit a red shifted emission barycenter in aqueous solution, and 
when bound to lipid bilayers the emission will blue shift to lower wavelengths. The 
change in the emission barycenter compared to that in absence of vesicles was plotted as a 
function of total lipid concentration (Figure 14).  Lipid composition of vesicles was either 100% 
DOPC, 3:1 DOPC:DOPG, 3:1 POPE:POPG. The results of this experiment show that there is 
varied behavior between indole percentage, lipid composition, and between the two different 
series (PAI & PGI). For PAI there is a larger blue shift at lower concentrations when the indole 
percentage is the highest, especially for anionic lipid compositions. The PAI series exhibits that 
when the indole percentage is the highest there is more significant binding at lower 
concentrations, however at 350 µM of lipid vesicle the lowest indole percentage shows the 
greatest shift. PGI shows similar results in the sense that when the indole percentage is 19% at 
350 µM there is more binding than when the indole percentage is higher. However, at lower 
concentrations when the indole percentage is 19% the binding is significantly less. Both show 
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significantly larger barycenter shifts when binding PG-containing, indicating that electrostatic 































Note. Polymer binding was assayed using fluorescence by titrating SUVs into a polymer 
containing sample with a final concentration of 2 μM. After each addition the spectral 
barycenter was calculated and then a Δ barycenter was calculated by taking the difference 
between the initial barycenter and that of each addition. Polymethacrylates that were 
assayed were (A) PAI-1, (B) PGI-1, (C) PAI-2, (D) PGI-2, (E) PAI-3, and (F) PGI-3. In 
all panels blue represents PC, orange 3:1 PC:PG, and grey 3:1 PE: PG. All data are 

































Note. Normalized emission spectra for PAI-1 (A), PGI-1 (B), PAI-2 (C), PGI-2 (D), PAI-
3 (E), and PGI-3 (F) polymers before (red) and after (blue) interacting with lipid vesicles. 
Data are representative spectra after subtraction of a background spectrum. All shifts 













 To gather more information into the bilayer interactions, the same quenching 
technque was used from the previous chapter were utilized. Acrylamide strongly 
quenches fluorescence of Trp residues in an aqueous environmentand but does not exert 
this effect if buried into the lipid bilayer. In this case, the fluorescence of the indole was 
monitored for quenching by acrylamide. Stern-volmer quenching plots were created to 
analyze the data and Ksv (slopes of a linear fit to the data) are shown in Table 3. The the trends 
represented by the data in table 3 are consistant with the barycenter shift data from figure 14. As 
stated previously the barycenter shift was greatest when the lipid compostion contained an 
anionic component. The quenching assay confirms this by the reduction of quenching between 
the polymer being solution (free) state and when bound to the anionic vesicles. When comparing 
the interactions between zwitter ionic vesicles and anionic vesicles, there is a sigficantly smaller 
KSV when bound to anionic vesicles than zwitterionic. However, an interesting result is that at 
higher indole percentage for either series shows a significantly lower Ksv value. This would 















PAI-1 2.42  ± 0.45 1.07  ± 0.78 1.07  ± 0.78 0.81  ± 0.11
PAI-2 3.40  ± 0.43 2.33  ± 0.47 1.24  ± 0.15 1.57  ± 0.20
PAI-3 4.07  ± 2.55 4.59  ± 0.28 4.30  ± 0.82 4.24  ± 0.89
PGI-1 5.26  ± 0.48 5.27  ± 0.48 3.00  ± 0.35 0.36  ± 0.24
PGI-2 7.64  ± 2.66 6.97  ± 0.74 4.99  ± 0.25 3.05  ± 0.26
PGI-3 6.07  ± 1.95 4.27  ± 0.02 4.64  ± 1.57 2.57  ± 0.69
PE:PG










Note. Abbreviations: DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPG, 1,2- 



































Note. Acrylamide quenching was performed on (A) PAI-1, (B)PGI-1, (C) PAI-2, (D) 
PGI-2, (E) PAI-3, and (F) PGI-3. Samples contained either no lipid vesicles (yellow), 
(blue) DOPC, (orange) PC:PG, and (grey) PE:PG. All samples contained a peptide 
concentration of 2 µM and lipid concentration of 250 µM for those that contained lipid 
vesicles. Data is corrected for inner filter effects, dilution, and are background subtracted. 








  The mechanism to cationic biocides are likely to mimic that of traditional 
membrane disrupting AMPs. Due to the similarities of the mode of actions the effect of 
charge and hydrophobicity on membrane permeabilization can be investigated the same 
as the previous chapter. A snapshot of the outer membrane permeabilization 30 minutes after 
the bacterial culture was exposed to polymers is shown in Figure 13B, with full time courses 
shown in figure 14. The lysine-tryptohan mimicing polymers (PAI) showed similar trends to that 
of the arginine-tryptophan mimicking polymers (PGI) however, PAI induced permeabilization 
more quickly. PAI-3 showed to have permeabilized the quickest between all polymer variations 
One possible explaination could be that the positively charged amide in the side chain allows for 
better electrostatic interactions. Interestingly enough, both series exhibited permeabilization 
occurred better at lower than max concentrations of the assay. Both polymer series exhibited this 
trend but it was most evident in the PGI series where smaller concentrations exhibited enhanced 
permeabilization. This could be attributed to aggregation occuring that would prevent interactions 
with the membrane. The PGI variants display this concept the best. The postively charged side 
chain that allows for better electrostatic interactions with the surface of the membrane may 
prevent aggregation, or reduce the effects aggregation may have on permeabilization. Although 
these polymers permeabilize the outer membrane, the results from the inner permeabilization 
assay displayed the opposite. A snap shot of the results after 30 minutes of exposure are displayed 
in figure 13A and a full time course in figure 15. These results elucidate that neither polymer 


























Notes. E. coli , (A) Inner membrane and (B) outer membrane permeabilization. For both 
panels PAI-1 is shown in blue, PAI-2 in orange, PAI-3 in grey, PGI-1 in yellow, PGI-2 in 
black, PGI-3 in green, and positive control represented by dark blue. All data are 
averages of three replicates and SD represented by error bars. Error bars are smaller than 
























Note. The data sets show absorbance at 486 which indicates the periplasmic enzyme β-
lactamase breaking down the substrate nitrocefin. Bacteria were exposed to (A) PAI-1, 
(B) PGI-1, (C) PAI-2, (D) PGI-2, (E) PAI-3, (F) PGI-3, (G) Polymyxin. The legend 
shows the colors that represent each concentration that starts from 1 mg/mL serially 
diluted down to .00156 mg/mL and 0 mg/mL being the negative control. Data represents 




























Note. These data sets show the breakdown of the ONPG substrate by the periplasmic 
enzyme β-galactocidase which is represented by the absorbance at 420 nm. Varying 
concentrations of (A) PAI-1, (B) PGI-1, (C) PAI-2, (D) PGI-2, (E) PAI-3, (F) PGI-3, (G) 
CTAB. The legend shows the colors that represent each concentration that starts from 1 
mg/mL serially diluted down to .00156 mg/mL and 0 mg/mL being the negative control. 





Hemolytic activity can be utilized in the same manner as it is for venom peptides and 
other AMPs. This activity is a valid approximation in assesing the potential for further research 
and development. If the hemolytic activity is too high for low concentrations than it wouldn’t be 
useful to develop that compound further . One of the bigger disadvantages to using polymers as 
antimcrobial agents is the cytoxicity. The hemolysis assay was preformed using the same ovine 
blood  (RBC) and positive control as described in chapter 2. The results of the hemolysis assay 
for all polymer variants are displayed in figure 13C. These results indicate a small amount of 
hemolytic activity coming from the largest concentration (0.1mg/mL). The largest precent of 




















































Notes. Hemolysis of RBCs. Data sets were normalized with the experimental data done 
on untreated RBCs (0% hemolysis) and RBCs treated with Triton X-100 (100% 
hemolysis). In these panels PAI-1 is shown in blue, PAI-2 in orange, PAI-3 in grey, PGI-
1 in yellow, PGI-2 in black, and PGI-3 in green. Panel (A) is a smaller scale (-4% to 10 
%) of panel (B) (-10% to 100%). All data are averages of three replicates and SD 




10-Doxyl nonadecane (10-DN) has similar  quenching features as acrylamide. 
However, acrylamide quenches the fluorescence of the Trp residue in aqueous solution 
[159-160]. 10-DN quenches fluorescence if the Trp residue is in a non-polar environment 
much like the lipid bilayer. This would suggest that the results from this quenching are 
almost the reciporcal to that of acrylamide, quenching will not happen if the Trp remains 
in aqueous environment. In this case, the quenching of fluorescence caused by the indole 
was monitored by using this assay to investigate the penetration of the indoles into the 
bilayer. The change in fluorescence intensity for each polymer variation is displayed in 
figure 21. The lipid  composition of vesicles were either 100% DOPC, 3:! PC:PG and 3:1 
PE:PG. These results showed  no trend in quenching in comparison to the results from the 
acrylamide quenching assay. For example, the results from the lipid binding experiment 
and acrylamide quenching assay suggest that the polymer has enhanced binding to 
annionic lipid compositions. However, as clear as those results were, an assesment like 


















Note. The following figure shows fluorescence intensity for each polymer exposed to 
different lipid compositions. Blue represents DOPC, orange represents PC:PG, and grey 
represents PE:PG. All data was corrected for background with and without 10-DN, SD is 











The work presented explains the investigation into the the effects of charge and 
hydrophibicity on polymethacrylate polymers. These results indicate that a balance 
between hydophobicity and cationic composition effect the antimicrobial activity greatly. 
When the cationic composition is higher, it leads to greater binding across a myriad of 
concentrations, however when looking the PGI series that lacks the cationic side chain 
only lower concentrations favored activity. 
 Cationic biocide polymers act in a similar fashion as AMPs where as their 
cationic nature allows for electrostatic interactions with the negatively charged bacterial 
membrane [146]. Sythnesized polymers can and have been used to mimick the features of 
AMPs while reducing the draw backs such as manufcaturing expense, easibility of 
production and chemcial alterations, and amendability in the intergration to drug delivery 
systems [84]. Cationic biocide polymers must be able to preform selectively between host 
cells and bacterial cell surfaces to have any further development as a potnential 
therapeutic. These results show a significant difference in binding affinitiy to model lipid 
vesicles. Both polymer series PAI and PGI show a significantly larger shift to binding to 
anionic lipid vesicles. This is indicative of the indole side chain undergoing a change in 
local environment a more non-polar one. All polymer variants caused a barycenter shift 
in zwitterionic lipid vesicles but the difference between that and 100% DOPC was 
drastically different. This would imply that the anionic component of those vesicles were 
the primary cause for binding. PAI-1 , PAI-2, PAI-3 seemed to show a greater affinity of 
binding compared to their PGI counterpart. The postively charged side chain could be 
responisble for this, allowing for more electrostatic interactions. 
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 This can be further elucidated through the results of the acrylamide quenching 
assay. This is shown by a consistently lower Ksv displayed by the PAI series. 
Interestingly enough, the acrylamide quenching assay showed that for the anionic lipid 
model that the more cationic variants had significantly more quenching. For example, 
there is larger shift in barycenter for PAI-3 (6% indole) than PAI-1 (33% indole) but 
PAI-1 showed significanlty less quenching. This could mean that although the 
electrostatic interactions allowed for the initial binding to the membrane, the greater 
hydrophibicity allowed for a deeper penetration into lipid bilayer. This becomes more 
evident by comparing the results of PAI-3 and PGI-3, where PGI-3 had even less 
quenching and more hydrophibicity. Currently, the aggregation state of the polymers as a 
function of concentration is being carried out using dynamic light scattering (DLS). This 
could effectively give the size of the polymethacrylate derivatives in solution. This study 
could give information on the relationship of aggregation and concentration. This could 
possibly show that  0.1 mg/mL is a high enough concentration to cause aggregation, 
preventing any signifcant quenching by 10-DN. 
 Finally there is a rather small amount of hemolytic activity which isn’t totally 
unexpected. Hydrophobicity has been known to directly impact the cytoxic and hemolytic 
activity of polymers [110,150]. To get a better understanding of the toxic profile of these 
polymers the hemolysis assay was an essential step. These results showed that as the ratio 
of cationic compostion increased, the hemolytic activity was signifanctly less. This was 
interesting to see considering that the lipid binding models showed binding to the zwitter 




Chapter 4  
Conclusions  
L1 Ponericin Data 
The data present in this thesis displays the hydrophobic substituated variants of 
the L1 peptide are membrane binding and can adopt an α-helical structure upon binding. 
The identity of the hydrophobic substiuents play a significant role in the antimicrobial 
acitvity of this peptide. A bulkier hydrophobic substiuent like phenylalanine had an over 
all better job at binding and permeabilizing of the membrane than smaller substituents 
like alanine and valine. Confirmation of the substituents could also play a role in 
antimicrobial activity. For example, L1L (leucine) showed signifcantly less binding and 
permemabilization than L1I (isoluecine), the substituents are isomers of each with 
isoleucine having a more rigid structure. These peptide variants showed secondary 
structures in zwitter ionic and anionic vesicles that could correlate to antimicrobial 
activity with the exception of the L1A variant. Peptides adopting α-helical  secondary 
strucutres is a common feature when investigating the membrane disrupting abilities of 
AMPs. However, as shown L1A forms a α-helical structure with little to no binding in 
lipid models as well as antmicrobial activity. This is evidence suggesting that the degree 
of hydrophobicity has a direct impact. The venom peptide L1 shows great potential as a 
selective antimicrobial platform because of its low hemolytic activity and tunable 
antimicrobial activity. Future studies can be done on the overall net charge, in 
combination of hydrophobic/hydrophilic balance. Another useful study could be done on 
using non-natural amino acids in attempts to solve problems with bioavailability while 
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maintaining the antmicrobial activity profile and provide important fundemental 
understandings for designing more effective and selective antimicrobial molecules. 
Polymethacrylate Data 
The data presented in this thesis shows that these polymethacrylate variants have 
similar characteristics as traditonal membrane disrupting AMPs. This becomes more 
prevalent in the lipid binding studies. The polymers bind better to anionic lipid vesicles 
than zwitter ionic suggesting electrostatic interactions is a primary mode of action. The 
data also suggests that there is a balance between the cationic charge and hydrophobicity 
of the polymethacrylate. When the side chain was cationic, binding to lipid models as 
well as antimicrobial activity was significantly higher. This balance also had an important 
role in hemolytic activity. The PAI series that contained the cationic side chain showed 
signifcantly less hemolytic activity regardless of the indole percentage. The increase 
hydrophobicity may have also lead to aggregation resulting in higher activity at lower 
concentrations of polymer. Future studies can be done to investigate the effects of the 
identity of cationic groups on antimicrobial activity. Overall, this study shows 
polymethacrylates as valid AMP mimetic polymer and a potential platform for a 
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